Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tor A. Hervig"'
Publikováno v:
Bioingeniøren, Vol 56, Iss 7, Pp 28-32 (2021)
Introduction: To allow eligible persons with hemochromatosis to become blood donors will be advantageous for these individuals and for the blood supply. In Førde Health Trust, eligible patients with hemochromatosis have been registered as blood dono
Externí odkaz:
https://doaj.org/article/f9c65e2de8d24ef991a23e08d0e90e58
Autor:
Heidi A Doughty, Tor Audun Hervig
Publikováno v:
The Lancet. Global health. 10(3)
Publikováno v:
Transfusion and Apheresis Science. 61:103487
When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for
Autor:
Michael, Hahn, Maria Elena Huanca, Condori, Atle, Totland, Einar K, Kristoffersen, Tor Audun, Hervig
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 140(12)
COVID-19 can lead to life-threatening disease. While awaiting vaccines or documented specific therapeutic agents, several alternative treatment options are under investigation. This is a case report of the first COVID-19 patient treated with convales
Autor:
Håkon S, Eliassen, Anders, Aandstad, Christopher, Bjerkvig, Theodor, Fosse, Tor, Audun Hervig, Heather F, Pidcoke, Geir, Strandenes
Publikováno v:
Transfusion. 56
To provide whole blood on the battlefield can be a challenge, but a buddy system protocol is both an elegant and the only currently available means to supply blood to a Special Forces team in far-forward locations. Our aim was to investigate donor-sa
Autor:
Ina, Nepstad, Håkon, Reikvam, Geir, Strandenes, John R, Hess, Torunn O, Apelseth, Tor A, Hervig
Publikováno v:
Blood transfusion = Trasfusione del sangue. 12(1)
In patients who have large bleeds, there is a tendency to transfuse more plasma and platelets than recommended in earlier guidelines, and accordingly many hospitals now provide "transfusion packages" with an intended red cell:platelet:plasma ratio of
Autor:
Claudia I Chapuy, Maria D Aguad, Rachel T Nicholson, James P AuBuchon, Claudia S Cohn, Meghan Delaney, Joan Cid, Walter Dzik, Mark K. Fung, Andreas Greinacher, Ai Leen Ang, Dana V. Devine, Nancy M Dunbar, Henk Garritsen, Lawrence T Goodnough, Ross Herron, Tor A. Hervig, C. Michael Knudson, Jose M Kutner, Frank Nizzi, Suchitra Pandey, Benjamin Rioux-Masse, Kathleen Selleng, Joseph Sweeney, Minoko Takanashi, Aaron A.R. Tobian, Lorna Wall, Silvano Wendel, David A Westerman, Meredith Unger, Parul Doshi, Michael F. Murphy, Larry J. Dumont, Richard M. Kaufman, The BEST Collaborative
Publikováno v:
Blood. 126:3567-3567
Introduction Daratumumab (DARA), an IgG1k human monoclonal antibody (Ab) against CD38, is a promising novel therapy for multiple myeloma. However, direct binding of DARA to endogenous CD38 on reagent red blood cells (RBCs) interferes with routine blo